Diagnosis and Treatment of Cutaneous Adverse Effects of Targeted Therapy, Antibody-Drug Conjugates, and Immunotherapy in Cancer Patients: A National Consensus Statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology

The document provides a comprehensive overview of the cutaneous adverse effects of targeted cancer therapies, antibody-drug conjugates, and immunotherapy, highlighting conditions such as papulopustular eruption, skin xerosis, hand-foot skin reactions, hair disorders, nail alterations, and skin pigmentation changes. It emphasizes the importance of early intervention and management strategies, including prophylaxis with emollients, photoprotection, and tetracyclines for PPE, and treatments like minoxidil and PRP for alopecia. The document also discusses the impact of immune checkpoint inhibitors, which cause skin toxicities in 30-50% of patients, and outlines a grading scheme for severity. Multidisciplinary collaboration is crucial for optimal patient care, with management strategies tailored to the severity of reactions, ranging from topical treatments to systemic interventions for severe cases.